Filing Flows › Health Care › Evolus (EOLS)
Evolus (EOLS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Evolus (EOLS) Q3 2026 earnings results →
Q3 2026 Revenue up 13% year over year to $78.0M · 16¢ of every $1 of revenue lost · operating margin -10.8%
Evolus made $78.0M in Q3 2026 (+13% Y/Y): Product revenue, net $77.2M, Service revenue $741K. Operating margin -10.8%, net loss $12.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $78.0M in Q3 2026, up 13% year over year and down 7% from the previous quarter. Product revenue, net was the largest line at 99% of revenue. Product revenue, net added $8.2M year over year (up 12%), 92% of the total change.
Gross margin was 65.0%, down 1.4 points from Q3 2025. Operating costs exceeded revenue by $8.4M, an operating margin of -10.8%. Operating expenses grew 3% against revenue growth of 13%. The fastest-growing cost line was Other operating costs (+70%). The quarter ended with a net loss of $12.5M, wider than the previous quarter's $8.1M loss.
Operating cash flow was −$1.9M. Non-cash charges added back $2.4M of depreciation and amortization and $5.6M of share-based compensation. Working capital and other items added $2.6M. Capital expenditures of $320K exceeded it, leaving free cash flow of −$2.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $78.0M | +13% | -10.8% | −$12.5M | −$1.9M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $84.1M | +21% | -5.4% | −$8.1M | −$3.6M |
| Q1 2026 | 10-Q | May 4, 2026 | $73.1M | +7% | -9.4% | −$10.7M | −$10.0M |
| Q4 2025 | 10-K | Mar 3, 2026 | $90.3M | +14% | 4.7% | $130K | $12.8M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $69.0M | +13% | -16.7% | −$15.7M | −$14.7M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $69.4M | +4% | -14.7% | −$17.1M | −$24.8M |
| Q1 2025 | 10-Q | May 7, 2025 | $68.5M | +16% | -22.1% | −$18.9M | −$15.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Evolus
We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.
In its own words, from its 10-K, filed Mar 3, 2026.
Evolus against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +13% against the peers' median +10%. Operating margin: -10.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EOLS Evolus | Q3 2026 | $78.0M | +13% | -10.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Evolus 10-Q on SEC EDGAR · CIK 1570562 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns EOLS and who is buying
More on EOLS
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results